Clinical Trial

Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation

Recruiting
View on ClinicalTrials.gov →
Summary
The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy/fraction). Validating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study "esSBRT"
Trial Details
NCT Number NCT06894628
Lead Sponsor Regina Elena Cancer Institute
Conditions Prostatic Neoplasms
Enrollment 103 participants
Start Date 2024-11-04
Primary Completion 2027-11-04 (estimated)
Study Completion 2027-11-04 (estimated)
Updated on ClinicalTrials.gov 2025-03-25